CN107970326A - 一种复方大山蚁粉片及其制备方法 - Google Patents
一种复方大山蚁粉片及其制备方法 Download PDFInfo
- Publication number
- CN107970326A CN107970326A CN201810060784.5A CN201810060784A CN107970326A CN 107970326 A CN107970326 A CN 107970326A CN 201810060784 A CN201810060784 A CN 201810060784A CN 107970326 A CN107970326 A CN 107970326A
- Authority
- CN
- China
- Prior art keywords
- parts
- mountain
- compound
- powder piece
- ant powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 66
- 150000001875 compounds Chemical class 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 244000286838 Eclipta prostrata Species 0.000 claims abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 24
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 24
- 235000008434 ginseng Nutrition 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 241000257303 Hymenoptera Species 0.000 claims abstract description 14
- 241000208340 Araliaceae Species 0.000 claims description 23
- 241000233948 Typha Species 0.000 claims description 22
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 239000004677 Nylon Substances 0.000 claims description 8
- 238000010009 beating Methods 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229920001778 nylon Polymers 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 210000004185 liver Anatomy 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 abstract description 5
- 230000036737 immune function Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000005229 liver cell Anatomy 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000001398 Typha domingensis Species 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 7
- 241000256602 Isoptera Species 0.000 description 4
- 230000003796 beauty Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- LYEFRAMOOLOUKA-RBXMUDONSA-N Iridomyrmecin Chemical compound [C@@H]1([C@@H](C(=O)OC2)C)[C@H]2[C@@H](C)CC1 LYEFRAMOOLOUKA-RBXMUDONSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- LYEFRAMOOLOUKA-UHFFFAOYSA-N isoepiiridomyrmecin Natural products C1OC(=O)C(C)C2C1C(C)CC2 LYEFRAMOOLOUKA-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/24—Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Insects & Arthropods (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及大山蚁粉片技术领域,具体涉及一种复方大山蚁粉片及其制备方法,该复方大山蚁粉片由如下重量份数原料制成:30‑40份大山蚁、1‑6份人参、5‑15份刺五加、2‑8份黄芪、3‑10份仙灵脾、2‑12份五味子、3‑9份蒲黄、1‑7份五灵脂、1‑6份旱莲草,本发明所提供的大山蚁粉片可以滋阴补血,延缓衰老,增加抗体形成细胞的数量,提高抗体效果;此外,还具有护肝养肝,调节免疫功能,改善肝脏血液循环,促进肝细胞再生的功效,疗效极好,无副作用,值得推广。
Description
技术领域
本发明涉及大山蚁粉片技术领域,具体涉及一种复方大山蚁粉片及其制备方法。
背景技术
大山蚁,是长白山红蚂蚁中个大、质量最好的一种,是长白山独有的珍贵药用动物,学名北方蚁,采集于纯天然、绿色、野生长白山靖宇矿泉城。大山蚁的食用、药用最早源于我国最早的词书《尔雅》以及明代李时珍的《本草纲目》上均有详细的记述。大山蚁对男性壮阳、女性美容、中老年人风湿病,类风湿病,儿童休弱及乙肝失眠都有良好的治疗作用。大山蚁营养成分丰富,作为高级营养保健食品,它能为人体提供各种营养物质,避免人体出现缺乏某种物质的可能性,还能起到增强食欲、消除疲劳、提神、助睡眠、美容等作用,使机体各***的生理功能处乇正常的平衡状态.另外,大山蚁体内的多种微量元素和特殊活性物质,具有抑菌,抗风湿、抗癌、抗炎止痛、抗过敏及护肝、平喘、镇静等药理作用。
目前中国专利CN104546925A公开了一种白蚁胶囊及其制备方法,仅采用白蚁干粉为主要原料,用中性脂肪酶和中性蛋白酶水解反应,加热回流和酶水解联用的条件下精制而成。是一种纯天然昆虫型生物反应调节剂(BRM),不仅有增强免疫的作用,协调机体消除体内异变细胞,形成肿瘤不适生存的内环境。从而促使肿瘤细胞自行萎缩,阻止其增殖、扩散和转移,而且是一种良好的乙型肝炎辅助治疗剂,能显著提高乙型肝患者免疫功能。
目前中国专利CN1136924A公开了一种纯天然蚂蚁胶囊及其加工方法。它是利用天然蚂蚁为原料,主要是以拟黑多刺蚁为原料,经过清杂、漂洗、烘干、磨粉、过筛、灭菌后制成纯天然蚂蚁粉,然后将蚂蚁粉用胶囊包装机包装制成透明蚂蚁胶囊。本品含有多种氨基酸、多种脂肪酸、大量微量元素以及维生素A、D、E、B12、B2等、多种酶类、蚁醛、臭蚁素等,是一种新型的良好营养源,它对免疫功能亢进的类风湿性关节炎有特殊效果,对促进儿童生长发育,增强耐力,提高人体健康素质,抗衰老具有较好的作用,是人类必不可少的一种纯天然保健品。
但现有的白蚁胶囊通常存在药用功效差的缺陷。
发明内容
针对上述存在的问题,本发明提出了一种复方大山蚁粉片及其制备方法。本发明提供的技术方案能够有效弥补现有的白蚁胶囊存在药用功效差的缺陷。
为了实现上述的目的,通过以下技术方案予以实现:
一种复方大山蚁粉片,该复方大山蚁粉片由如下重量份数原料制成:30-40份大山蚁、1-6份人参、5-15份刺五加、2-8份黄芪、3-10份仙灵脾、2-12份五味子、3-9份蒲黄、1-7份五灵脂、1-6份旱莲草。
优选的,该复方大山蚁粉片由如下重量份数原料制成:32-38份大山蚁、2-5份人参、6-14份刺五加、3-7份黄芪、4-9份仙灵脾、3-10份五味子、2-8份蒲黄、2-6份五灵脂、2-5份旱莲草。
优选的,该复方大山蚁粉片由如下重量份数原料制成:34-36份大山蚁、3-4份人参、7-10份刺五加、4-6份黄芪、5-8份仙灵脾、5-8份五味子、3-7份蒲黄、3-5份五灵脂、3-4份旱莲草。
优选的,该复方大山蚁粉片由如下重量份数原料制成:35份大山蚁、3份人参、7份刺五加、5份黄芪、7份仙灵脾、6份五味子、5份蒲黄、4份五灵脂、3份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在50-55℃条件下干燥1-2h,打粉后混合均匀,用2-4%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于一定温度下干燥1-2h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
优选的,所述步骤(1)中大山蚁颗粒过80-100目筛。
优选的,所述步骤(2)中非离子纤维素混合醚为羟丙基甲基纤维素。
优选的,所述步骤(2)中湿颗粒干燥温度为50-60℃。
采用上述的技术方案,本发明的有益效果如下:本发明中,大山蚁对男性壮阳、女性美容、中老年人风湿病,类风湿病,儿童休弱及乙肝失眠都有良好的治疗作用;人参、刺五加、黄芪、仙灵脾、五味子配伍,能够明显提高细胞产生诱生干扰素的能力,增强网状内皮***的吞噬能力、腹腔巨噬细胞的吞噬能力,促进淋巴细胞转化,增强细胞免疫能力;蒲黄、五灵脂、旱莲草配伍,可以用于风湿痹痛、筋骨拘挛,能够有效的延缓运动性疲劳的发生,加速运动后机体若干生理生化指标的恢复,从而具有明显的抗运动型疲劳作用。
本发明中所提供的复方大山蚁粉片给人服用后,可以滋阴补血,延缓衰老,增加抗体形成细胞的数量,提高抗体效果;此外,本发明中所提供的复方大山蚁粉片还具有护肝养肝,调节免疫功能,改善肝脏血液循环,促进肝细胞再生的功效,疗效极好,无副作用。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述。基于本发明的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种复方大山蚁粉片,该复方大山蚁粉片由如下重量份数原料制成:30份大山蚁、6份人参、5份刺五加、8份黄芪、3份仙灵脾、12份五味子、3份蒲黄、7份五灵脂、1份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过80目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在50℃条件下干燥2h,打粉后混合均匀,用2%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于50℃下干燥1h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
实施例2
一种复方大山蚁粉片,该复方大山蚁粉片由如下重量份数原料制成:40份大山蚁、1份人参、15份刺五加、2份黄芪、10份仙灵脾、2份五味子、9份蒲黄、1份五灵脂、6份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过100目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在55℃条件下干燥1h,打粉后混合均匀,用4%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于50℃下干燥2h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
实施例3
一种复方大山蚁粉片,该复方大山蚁粉片由如下重量份数原料制成:32份大山蚁、5份人参、6份刺五加、7份黄芪、4份仙灵脾、10份五味子、2份蒲黄、6份五灵脂、2份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过85目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在50℃条件下干燥1h,打粉后混合均匀,用3%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于50℃下干燥1h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
实施例4
一种复方大山蚁粉片,该复方大山蚁粉片由如下重量份数原料制成:38份大山蚁、2份人参、14份刺五加、3份黄芪、9份仙灵脾、3份五味子、8份蒲黄、2份五灵脂、5份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过90目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在50℃条件下干燥1h,打粉后混合均匀,用3%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于55℃下干燥1h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
实施例5
该复方大山蚁粉片由如下重量份数原料制成:36份大山蚁、3份人参、10份刺五加、4份黄芪、8份仙灵脾、5份五味子、7份蒲黄、3份五灵脂、4份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过95目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在55℃条件下干燥2h,打粉后混合均匀,用3%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于55℃下干燥1h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
实施例6
该复方大山蚁粉片由如下重量份数原料制成:35份大山蚁、3份人参、7份刺五加、5份黄芪、7份仙灵脾、6份五味子、5份蒲黄、4份五灵脂、3份旱莲草。
该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过95目筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在60℃条件下干燥2h,打粉后混合均匀,用3%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于55℃下干燥1h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
将本发明提供的复方大山蚁粉片与市售大山蚁胶囊作对风湿病患者、肝炎患者和剧烈运动者做比性能测试,测试结果如下:
风湿病患者/% | 肝炎患者/% | 剧烈运动者 | |
实施例1 | 35 | 71 | 服用0.5h后,疲劳感消失 |
实施例2 | 34 | 69 | 服用0.5h后,疲劳感消失 |
实施例3 | 37 | 68 | 服用0.5h后,疲劳感消失 |
实施例4 | 36 | 70 | 服用0.5h后,疲劳感消失 |
实施例5 | 35 | 69 | 服用0.5h后,疲劳感消失 |
实施例6 | 36 | 70 | 服用0.5h后,疲劳感消失 |
对照例 | 21 | 40 | 服用1h后,疲劳感消失 |
由上表可以看出,本发明提供的复方大山蚁粉片对风湿病患者和肝炎患者的作用明显强于市售的大山蚁胶囊的作用,说明本发明提供的复方大山蚁粉片具有减轻风湿病患者病情,调节免疫功能,改善肝脏血液循环,促进肝细胞再生的功效;此外,本发明提供的复方大山蚁粉片对于剧烈运动者作用更明显,加速了运动后机体若干生理生化指标的恢复,从而具有明显的抗运动型疲劳作用。
以上实施例仅用以说明本发明型的技术方案,而非对其限制;尽管参照前述实施例对本发明型进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明型各实施例技术方案的精神和范围。
Claims (8)
1.一种复方大山蚁粉片,其特征在于,该复方大山蚁粉片由如下重量份数原料制成:30-40份大山蚁、1-6份人参、5-15份刺五加、2-8份黄芪、3-10份仙灵脾、2-12份五味子、3-9份蒲黄、1-7份五灵脂、1-6份旱莲草。
2.根据权利要求1所述的复方大山蚁粉片,其特征在于,该复方大山蚁粉片由如下重量份数原料制成:32-38份大山蚁、2-5份人参、6-14份刺五加、3-7份黄芪、4-9份仙灵脾、3-10份五味子、2-8份蒲黄、2-6份五灵脂、2-5份旱莲草。
3.根据权利要求1所述的复方大山蚁粉片,其特征在于,该复方大山蚁粉片由如下重量份数原料制成:34-36份大山蚁、3-4份人参、7-10份刺五加、4-6份黄芪、5-8份仙灵脾、5-8份五味子、3-7份蒲黄、3-5份五灵脂、3-4份旱莲草。
4.根据权利要求1所述的复方大山蚁粉片,其特征在于,该复方大山蚁粉片由如下重量份数原料制成:35份大山蚁、3份人参、7份刺五加、5份黄芪、7份仙灵脾、6份五味子、5份蒲黄、4份五灵脂、3份旱莲草。
5.根据权利要求1-4任一项所述的复方大山蚁粉片,其特征在于,该复方大山蚁粉片的制备方法包括如下几个步骤:
(1)将大山蚁晒干,粉碎过筛,备用;
(2)将人参、刺五加、黄芪、仙灵脾、五味子、蒲黄、五灵脂、旱莲草在50-55℃条件下干燥1-2h,打粉后混合均匀,用2-4%的非离子纤维素混合醚溶液制备软材,过20目尼龙筛制粒,湿颗粒于一定温度下干燥1-2h,备用;
(3)将上述步骤所得物料混合均匀,用适当的压力压片,得复方大山蚁粉片。
6.根据权利要求5所述的新型复方大山蚁粉片的制备方法,其特征在于,所述步骤(1)中大山蚁颗粒过80-100目筛。
7.根据权利要求5所述的新型复方大山蚁粉片的制备方法,其特征在于,所述步骤(2)中非离子纤维素混合醚为羟丙基甲基纤维素。
8.根据权利要求5所述的新型复方大山蚁粉片的制备方法,其特征在于,所述步骤(2)中湿颗粒干燥温度为50-60℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810060784.5A CN107970326A (zh) | 2018-01-22 | 2018-01-22 | 一种复方大山蚁粉片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810060784.5A CN107970326A (zh) | 2018-01-22 | 2018-01-22 | 一种复方大山蚁粉片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107970326A true CN107970326A (zh) | 2018-05-01 |
Family
ID=62006270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810060784.5A Pending CN107970326A (zh) | 2018-01-22 | 2018-01-22 | 一种复方大山蚁粉片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107970326A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091654A (zh) * | 1993-03-01 | 1994-09-07 | 金陵老年病康复医院 | 蚂蚁乙肝宁 |
CN1113778A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 老年病制剂 |
CN1686321A (zh) * | 2005-03-29 | 2005-10-26 | 葛强 | 蚁参药酒 |
CN1706477A (zh) * | 2005-04-11 | 2005-12-14 | *** | 具有延缓衰老功效的保健胶囊 |
-
2018
- 2018-01-22 CN CN201810060784.5A patent/CN107970326A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1091654A (zh) * | 1993-03-01 | 1994-09-07 | 金陵老年病康复医院 | 蚂蚁乙肝宁 |
CN1113778A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 老年病制剂 |
CN1686321A (zh) * | 2005-03-29 | 2005-10-26 | 葛强 | 蚁参药酒 |
CN1706477A (zh) * | 2005-04-11 | 2005-12-14 | *** | 具有延缓衰老功效的保健胶囊 |
Non-Patent Citations (7)
Title |
---|
北京山健生物科技有限公司: "长白山山健大山蚁胶囊", 《365园林网》 * |
孙永年: "蚂蚁乙肝宁对慢性乙肝、肝纤维化疗效观察", 《人民军医》 * |
张英: "《药酒生产实用技术》", 30 June 2006, 中国轻工业出版社 * |
徐蓉等: "《药物制剂综合实训》", 31 August 2013, 东南大学出版社 * |
王云云: "《药物制剂技术》", 31 August 2016, 重庆大学出版社 * |
苏蕊等: "长白山大山蚁抗疲劳功效研究", 《亚太传统医药》 * |
董方言: "《现代实用中药新剂型新技术》", 30 April 2001, 人民卫生出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106165883A (zh) | 一种素食全餐及其制备方法 | |
CN100563697C (zh) | 红景天沙棘片及其制备方法 | |
CN106399030A (zh) | 一种保健荔枝甜酒及其制备方法 | |
CN104940606A (zh) | 调理八种偏颇体质的鹿胶保健品 | |
CN109645200A (zh) | 一种玛咖压片糖果及其制备方法 | |
CN106174485A (zh) | 具有强肾壮阳功效的酵素组合物、泡腾片及制备方法 | |
CN106072578A (zh) | 具有增强人体免疫功能的酵素组合物、泡腾片及制法 | |
CN105838545A (zh) | 一种山楂酒酒饼及其制作方法 | |
CN105341668A (zh) | 一种藜麦养生粥 | |
CN105494844A (zh) | 一种枸杞压片糖果生产方法 | |
CN104740541B (zh) | 一种保肝解毒恢复肝功能的保健中药粉 | |
CN103584022A (zh) | 一种补血养气的藕粉及其制备方法 | |
CN105286009A (zh) | 具有保健功能食品颗粒剂及其用途 | |
CN107960508A (zh) | 一种补肾和消除疲劳、改善睡眠的压片糖果 | |
CN104783164A (zh) | 一种用于阴虚体质的阿萨伊果保健品 | |
CN101104006B (zh) | 一种冬虫夏草菌提取浓缩液的制备方法及其应用 | |
CN102266487B (zh) | 治疗高脂血症的含葛根组合物及制备方法和应用 | |
CN108967536A (zh) | 牛大力酸奶及其制备方法 | |
CN105533233A (zh) | 一种防治家禽寄生虫病的中药饲料配方 | |
CN108143974A (zh) | 解酒护肝丸 | |
CN104522572A (zh) | 一种补气益脾的葛根粉 | |
CN105852061A (zh) | 一种百香果酵素及其制备方法 | |
CN107970326A (zh) | 一种复方大山蚁粉片及其制备方法 | |
CN104171110A (zh) | 一种养胃白茶 | |
CN103301342A (zh) | 一种促进生发中药制剂的配方及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180501 |
|
RJ01 | Rejection of invention patent application after publication |